Relating to: prohibiting step therapy protocols for certain cancer drugs.

SB 765 prohibits health insurers and pharmacy benefit managers from requiring step therapy protocols for certain cancer treatments. Specifically, it bans forcing patients to try less expensive drugs first before covering FDA-approved medications for metastatic cancer or related side effects (like severe treatment complications) that worsen health if untreated. The law applies only when the drug is consistent with medical best practices and supported by evidence-based research. This directly affects patients with advanced cancer and their insurers, ensuring faster access to prescribed treatments without unnecessary prior authorization hurdles.